Disseminated intracranial xanthoma disseminatum: a rare case report and review of literature

Guang-Zhi Yang, Jing Li and Lu-Ping Wang

Abstract

Background: Xanthoma disseminatum (XD) is a rare benign histiocytic proliferating disease of non-Langerhans cell origin, which is clinically mainly characterized by cutaneous or mucous lesions. Although XD is acknowledged of one systematic disease, involvement of the central nervous system is quite rare.

Case presentation: We presented one 34-year-old Chinese female with disseminated intracranial XD without cutaneous or oral mucosal papules and masses of the other organs. MR imaging displayed multiple heterogeneous masses with intense enhancement in the right frontal lobe, temporal lobe, corpus callosum, left cuneus, suprasellar region, and right cerebellum. Pathological examination showed a neoplastic lesion composed of plentiful epitheloid or spindle cells. The cell had pink cytoplasm of vacuolation and foam with deviated nucleus absent of atypia and mitosis. The histiocytic markers including CD163, CD11c, Mac387 and CD68 were positive, whereas S-100, CD1a, GFAP, CD21, CD23 and so on were negative immunohistochemically.

Conclusions: Intracranial XD without systemic involvement was extremely rare, which was supposed to be considered in differential diagnosis with other neoplasms of histiocytic origin or gliomas.

Keywords: Xanthoma disseminatum, Disseminated, Histiocytic neoplasm, MR, Immunohistochemistry

Background

Xanthoma disseminatum (XD) is a rare benign histiocytic proliferating disease of non-Langerhans cell origin [1, 2]. It is clinically mainly characterized by a number of symmetrically distributed cutaneous yellow-brown papules, often affecting faces, trunk and limbs. XD may also involve the mucous membranes of conjunctivae, lips, tongue, cheeks, gingiva, palate, and so on. Respiratory tract, including the pharynx, larynx, trachea and bronchi, is sometimes involved. In addition, involvement of the viscera has been occasionally reported [3–5]. Although XD is always a systemic disease [3], involvement of the central nervous system (CNS) is quite rare, and until now less than 100 cases in the literature written in English have been reported. In our medical practice, we experienced with one rare case of intracranial XD without involvement of other organs.

Herein, we presented the case and discussed with review of the literature.

Case presentation

One 34-year-old Chinese female presented with 1-month history of dizziness, nausea, and vomiting, and followed by difficulty in swallowing and walking instability. Physical examinations revealed no significant abnormality. Laboratory tests showed that results of complete blood count and biochemical profiles were roughly normal. Brain magnetic resonance (MR) imaging displayed multiple heterogeneous masses with intense enhancement in the right frontal lobe, temporal lobe, corpus callosum, left cuneus, suprasellar region, and right cerebellum (Figs. 1 and 2). Diagnosis of lymphoma was preferred and biopsy was performed in the right cerebellum then.

The samples obtained at surgery were fixed in 10 % buffered formalin and embedded in paraffin for pathological study. Sections were stained by Hematoxylin-Eosin for routine histopathological investigation. Immunohistochemical analysis was performed by steam heat-
induced epitope retrieval and the Dako Envision Detection System.

Pathological examination showed a neoplastic lesion composed of plentiful epitheloid or spindle cells instead of the normal cerebellum (Fig. 3). The cells had numerous pink cytoplasm of vacuolation and foam with deviated nucleus. Atypia and mitotic figures were nearly absent. There were also a few mature lymphocytes infiltrating, especially around focal vessels.

Immunohistochemical studies displayed that CD163, CD11c, Mac387 and CD68 (both KP1 and PGM clones) were diffusely positive, which verified that the neoplasm cells were of histiocytic origin (Fig. 4a). CD3 was scattered positive for the small T lymphocytes (Fig. 4b). Other markers, including S-100, CD1a, glial fibrillary acidic protein (GFAP), oligo-2, CD21, CD23, CD35, CD30, CD20, Melan-A and HMB45, were all negative, which excluded Langerhans cell histiocytosis (LCH), glioma, lymphoma, and follicular dendritic cell sarcoma, and so on. The pathological diagnosis was disseminated intracranial XD.

In the comprehensive examinations during the preoperative preparation, no mass in the internal organs, including the liver, gallbladder, kidneys, pancreas, bladder, uterus, and ovary examined by B ultrasound and lungs scanned by computed tomography (CT), was found. No cutaneous or oral mucosal papules were found after careful consultation from the dermatologist since XD was diagnosed morphologically. So diagnosis of intra-axial brain XD without systemic involvement was established.

The patient hadn’t received any treatments after surgery. Follow-up for 1 year showed that the lesions had still kept stable.

Discussions
XD, also named as Montgomery syndrome, was first described by Von Graefe in 1867, and then reviewed and credited by Virchow in 1871 [6]. It is reported that XD affected populations aged from 5 months to 70 years old with most before 25 years old. It is more prevalent in males with a male-to-female ratio of 2:1 [7]. No typical inheritance pattern is confirmed. XD is a histiocytic disorder of non-Langerhans cell origin morphologically characterized by xanthomatous deposits in the absence of lipid metabolism disorder and hyperlipidemia [8].
Although it is widely acknowledged that XD is a systemic disease, involvement of CNS is quite rare [9]. Clinical manifestations of patients with CNS XD varied greatly according to the involving positions, including headache, nausea, vomiting, dizziness, seizures, ataxia, or visual field defects. Hammond and Mackenzie reviewed the literatures and summarized that less than 100 cases of CNS XD had been reported [6]. XD always affects the dura mater, which is actually extra-axial [10]. The first axial case located in the pontine was reported by Chiari [6]. Most cases involving the parenchymal CNS are located in the pituitary or hypothalamus, whereas the number of the outside is less than 5 % [11]. It is believed that besides the pituitary and hypothalamus, the brainstem and cerebellum were always involved because of the local environment such as the blood–brain barrier and short distance from the ventricle or meninges [6].

The exact diagnosis of XD is relied on pathological examination, and other neoplasms of histiocytic origin such as LCH and Rosai-Dorfman disease (RDD) are under differential diagnosis. Typical histopathological manifestations of XD are large pleomorphic cells with cytoplasmic bubbles, which can merge and form multinucleated Toutan giant cells. Inflammation is not striking, and varying number of mature T lymphocytes is mixed in the lesion. By immunohistochemistry, the tumor cells are positive for histiocytic markers including CD68, CD163, CD11c and so on, whereas negative for S-100 protein and CDla. Eosinophils are one of components in LCH, and nuclear grooves are the prominent feature of the tumor cells. In addition, immunohistochemical S-100 and CDla are positive, and Birbeck bodies are detected under electron microscopic examination, which can be identified from XD. Inflammatory background is striking in RDD, and the tumor cells are remarkably huge with intracytoplasmic small lymphocytes swallowed and immunohistochemically S-100 positive. Sometimes, intraparenchymal XD is also supposed to be distinguished from Pleomorphic xanthoma astrocytoma (PXA), and immunohistochemical staining of GFAP is crucial [12].

Since XD is always one systemic disease, cutaneous or mucous biopsy is supposed to perform before diagnosis. Serum lipid examination is also necessary. However, our case is quite distinct, which multiple locations of CNS were involved and no other differences were founded, including skin or mucous papules, masses of the other organs besides serum lipid.

According to natural course and outcome, XD was divided into three clinical types by Caputo [13]. The most
common is persistent form, followed by progressive form with systemic involvement, and the rare is regression form. Thus, XD seems to have self-healing tendency. Besides, as far as XD with intracranial involvement is concerned, prognosis is also closely related with the involving location. Hammond and Mackenzie reported that fatality rate of XD patients with the pituitary/the hypothalamus was 63%, and yet that of the posterior fossa was 100% [11]. For cases with intracranial XD, symptoms progress is supposed to be observed and mass change should be reviewed by MR imaging to determine the clinical types and following therapies. The present case was identified of persistent form in the follow-up, thus operation seemed unnecessary, and yet no accurate diagnosis was established until operation.

Treatments for intracranial XD remain determined because of limited cases and paradoxical results [11, 14]. Steroids or combined with chemotherapy drugs were usually adopted for cases with intracranial wide-spread or large mass. It is generally believed that the radiotherapy had no satisfactory effect for intracranial XD, but multi-mode radiation may have some effect. Surgery was always the choice for localized XD. So, it is easy to see different strategies for different cases, but dynamic observation is the premise. In principle, clinical treatments such as surgery or chemotherapy were performed for the cases with progress or large volume, dynamic observation was taken for the cases of self-limited tendency or slow progress without obvious symptoms.

Conclusions
Here, we presented the case of intracranial XD without systemic involvement. MR imaging displayed multiple heterogeneous masses with intense enhancement. Pathological examination showed a neoplasm composed of plentiful epitheloid or spindle cells with vacuolated and foamy pink cytoplasm. The tumor cells were absent of atypia and positive for histiocytic markers immunohistochemically. Such case was extremely rare, which was supposed to be considered in differentiation with other neoplasms of histiocytic origin or gliomas.

Abbreviations
CNS, central nervous system; CT, computed tomography; GFAP, glial fibrillary acidic protein; LCH, langerhans cell histiocytosis; MR, magnetic resonance; PXA, pleomorphic xanthoastrocytoma; RDD, rosai-dorfman disease; XD, xanthoma disseminatum

Funding
There was no funding for this article.

Availability of data and material
Data and materials of this work are available on request by the corresponding author.

Authors’ contributions
GY performed the pathological observation and immunohistochemistry and collected the clinical information. JL made the pathological diagnosis and made up the manuscript. LW participated in manuscript revision. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
A statement of ethics approval for this case report by the General Hospital of Beijing Military Command is available on request.

Received: 17 April 2016 Accepted: 9 August 2016
Published online: 17 August 2016

References
1. Jin S, Chae SY, Chang SE, Suh C, Lee SW, Ryu JS. A case of xanthoma disseminatum: evaluation and monitoring by 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Br J Dermatol. 2014;170:1177–81.
2. Park M, Boone B, Devos S. Xanthoma disseminatum: case report and mini-review of the literature. Acta Dermato-Venereol. 2014;2:150–4.
3. Atta AM, Bakry OA, Mohamed EE. Xanthoma disseminatum: a progressive case with multisystem involvement. J Postgrad Med. 2014;60:69–71.
4. Rupec RA, Schaller M. Xanthoma disseminatum. Int J Dermatol. 2002;41:911–3.
5. Pinto ME, Escalaya GR, Escalaya ME, Pinto JL, Chian CA. Xanthoma disseminatum: case report and literature review. Endocr Pract. 2010;16:1003–6.
6. Hammond RR, Mackenzie IR. Xanthoma disseminatum with massive intracranial involvement. Clin Neuropathol. 1995;14:314–21.
7. Zak IT, Altinok D, Neilsen SS, Kish KK. Xanthoma disseminatum of the central nervous system and cranium. Am J Neuroradiol. 2006;27:919–21.
8. Mishkel MA, Cockshott WP, Nazir DJ, Rosenthal D, Spaulding WP, Wynn-Williams A. Xanthoma disseminatum. Clinical, metabolic, pathologic, and radiologic aspects. Arch Dermatol. 1977;113:1094–100.
9. Knobler RM, Neumann RA, Gebhart W, Radaskiewicz T, Ferenci P, Widholm K. Xanthoma disseminatum with progressive involvement of the central nervous and hepatobilary systems. J Am Acad Dermatol. 1992;23:341–6.
10. Chepuri NB, Challa VR. Xanthoma disseminatum: a rare intracranial mass. Am J Neuroradiol. 2003;24:105–8.
11. Oka M, Oniki S, Kornatsu M, Ikeda T, Matsuo M, Miyamoto Y, Akita H, Kondo T, Nishigori C. Xanthoma disseminatum with intracranial involvement: case report and literature review. Int J Dermatol. 2010;49:193–9.
12. Vozcaino MA, Cacchino DV, Fox E, Rodriguez FJ. Pleomorphic xanthoastrocytoma: report of two cases with unconventional clinical presentations. Clin Neuropathol. 2014;33:380–7.
13. Caputo R, Veraldi S, Gianotti R, Tosti A, Varotti C, de Kaminsky AR. The various clinical patterns of xanthoma disseminatum. Considerations on seven cases and review of the literature. Dermatol. 1995;190:19–24.
14. Kalz F, Hoffman MW, Lafance A. Xanthoma disseminatum. Clinical and laboratory observations over a ten year period. Dermatologica. 1970;140:29–41.